Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

VIDEX EC

DIDANOSINE

Standard Dose
250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview VIDEX EC is listed in Drugs@FDA under application 021183 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DIDANOSINE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2018-12-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview VIDEX EC is listed in Drugs@FDA under application 021183 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DIDANOSINE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2018-12-17 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Discontinued
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.